## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average	burden					
hours per response	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Typ	e Responses	)														
1. Name and Address of Reporting Person *- Baynes Roy D.				2. Issuer Name and Ticker or Trading Symbol Atara Biotherapeutics, Inc. [ATRA]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  _X_ Director 10% Owner				
(Last) (First) (Middle) 611 GATEWAY BOULEVARD, SUITE 900				3. Date of Earliest Transaction (Month/Day/Year) 06/23/2022							-	Officer (give	e title below)	Oth	er (specify belo	w)
(Street) SOUTH SAN FRANCISCO, CA 94080				4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line)  X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui								ired, Disposed of, or Beneficially Owned				
1.Title of Se (Instr. 3)				2A. Deemed Execution Dat any (Month/Day/Y		ate, if (	. Tran Code Instr.	8) (1	A Securities Acque A) or Disposed of Instr. 3, 4 and 5)  (A) or Amount (D)		of (D)	D) Owned Followin Transaction(s) (Instr. 3 and 4)		ecurities Beneficially ing Reported		7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common	Stock		06/23/2022				A		20,500	A	\$ 0 4	43,500			D	
			Table II -				•	in this	form are s a curi	e not re rently v	equired valid OM ficially O	collection of to respond IB control n	unless the		ea SEC	1474 (9-02)
	2. Conversion or Exercise Price of Derivative Security		Execution Date, if	4. 5. Transaction of Code Se (Instr. 8) Ac or of (Ir		5. Numb	per vative es d (A) osed	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	Ownersh Form of Derivati Security Direct (I or Indirects)	(Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expira e Date	ition	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Non- Qualified Stock Option (Right to Buy)	\$ 7.35	06/23/2022		A		31,500		(2)	06/22	2/2032	Comm	131.500	\$ 0	31,500	D	

#### **Reporting Owners**

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Baynes Roy D. 611 GATEWAY BOULEVARD SUITE 900 SOUTH SAN FRANCISCO, CA 94080	X						

### **Signatures**

/s/ David Tucker, Attorney-in-Fact	06/27/2022
**Signature of Reporting Person	Date

#### **Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These restricted stock units shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.
- (2) The option shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.